Kite CEO Christi Shaw to depart Gilead CAR-T unit
Christi Shaw will leave her post as CEO of Gilead’s Kite Pharma at the end of this quarter, Gilead said Friday morning.
Shaw led the CAR-T cell therapy company since 2019, more than a year after Gilead swooped in to buy the biotech for about $12 billion.
She oversaw a cell therapy maker that delivered its CAR-T treatments, Yescarta and Tecartus, to about 13,000 patients in more than 20 countries following the former’s first approval in 2017, Gilead said. The biopharma is one of a few to have so far received FDA clearance for autologous cell therapies, as the industry tries expanding the therapeutic tools’ scope from blood cancers to other areas of oncology.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters